" I am profoundly concerned that Catalyst's actions will cause patients to suffer or die. "
"How many patients will suffer from the cost price of $ 375,000?"
However, Sanders' letter also notes that the company has said many Firdapse patients will pay about $ 10 out of pocket each month, and he asked for more detail about that claim.
Sanders asked the company to respond by February 18. When contacted by CNN, Catalyst said it had no immediate response.
Patients had been able to get a version of the drug for free through a compliant use program through the US Food and Drug Administration. In November, the North American license for Firdapse acquired and then announced in December 13, phone call with investors, its intention to set the list price at $ 375,000, according to the letter.
"By setting such a high price and forcing production and distribution of the older, inexpensive version to cease, you are threatening access to patients with a cheap version of this product, and a completely unwarranted bill to American taxpayers," Sanders wrote.
The letter comes at a time when Americans have grown in the increasing prices of pharmaceuticals, with President Trump and lawmakers on both sides of the aisle saying more needs to be done to curb skyrocketing prices.